Li Tingting, Ke Yuehai, Cheng Hongqiang
Department of Pathology and Pathophysiology, Zhejiang University School of Medicine, Hangzhou 310058, China.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2016 May 25;45(5):544-549. doi: 10.3785/j.issn.1008-9292.2016.09.15.
Asthma is a phenotypically heterogeneous chronic disease of the airways. Studies have found that neutrophils are crucial to airway inflammation in acute asthma, persistent asthma, particularly in asthma of poor response to glucocorticoid treatment. The role of neutrophils in development of bronchial asthma is complex, as they can release a potent source of cytokines and inflammatory mediators participating in asthma. Differing from eosinophilic inflammatory asthma, neutrophilic inflammatory asthma is not depend on helper T (Th)2 cells, but may be related to Th1 and Th17 cells. This review highlights the role of neutrophils in the development of asthma, and the treatment of neutrophilic asthma with biological agents and novel small molecules.
哮喘是一种气道表型异质性的慢性疾病。研究发现，中性粒细胞在急性哮喘、持续性哮喘，尤其是对糖皮质激素治疗反应不佳的哮喘的气道炎症中起关键作用。中性粒细胞在支气管哮喘发展中的作用较为复杂，因为它们能释放参与哮喘的细胞因子和炎症介质的强大来源。与嗜酸性粒细胞性炎症哮喘不同，中性粒细胞性炎症哮喘不依赖辅助性T（Th）2细胞，而可能与Th1和Th17细胞有关。本文综述强调了中性粒细胞在哮喘发展中的作用，以及生物制剂和新型小分子对中性粒细胞性哮喘的治疗。
